Calyx Supply Simulation Service Launched
Service uses simulation modeling methodology to evaluate the quantity of medication produced for use in clinical development.
E-Clinical and Regulatory solutions and services provider Calyx has announced its Calyx Supply Simulation clinical trial supply forecasting service. Available through the company’s in-house statistical design and trial supplies consultants, the service uses simulation modeling methodology and over 50 design parameters that closely mimic an Interactive Response Technology (IRT) system, to evaluate the quantity of medication produced for use in clinical development.
By providing better-aligned medication scenarios—for trial start-up and continued enrollment, how long an existing amount of study medication will last and determining optimal site and depot buffer stock quantities—can help sponsors reduce cost and excessive drug wastage.
Reference: Calyx Launches Supply Simulation Service to Forecast and Optimize Clinical Trial Supplies; Nottingham, England and Morrisville, NC. March 7, 2023
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
